Tariffs, AI boom could test global growth’s resilience, OECD says

Investing.comTuesday, December 2, 2025 at 10:07:02 AM
Tariffs, AI boom could test global growth’s resilience, OECD says
  • The OECD has indicated that rising tariffs and the rapid growth of artificial intelligence (AI) could challenge the resilience of global economic growth. This assessment highlights the potential risks posed by trade tensions and technological advancements that may disrupt established economic patterns.
  • This development is significant as it underscores the OECD's role in monitoring global economic trends and providing insights that could influence policy decisions among member countries. The organization's findings may prompt governments to reassess their economic strategies in light of these challenges.
  • The interplay between tariffs and AI growth reflects broader economic dynamics, including the stabilization of US stocks amid cautious investor sentiment and the muted expectations for interest rate cuts in the Eurozone. Additionally, concerns about geopolitical risks and the impact of tax policies in various regions further complicate the economic landscape, suggesting a complex path ahead for global markets.
— via World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended apps based on your readingExplore all apps
Continue Readings
Desale Pravin, SVP at Lattice Semi, sells $399k in shares
NeutralFinancial Markets
Desale Pravin, Senior Vice President at Lattice Semiconductor, has sold $399,000 worth of shares in the company, a transaction reported by Investing.com. This sale reflects Pravin's financial decisions regarding his stake in Lattice Semi, a key player in the semiconductor industry.
Bellevue Gold stock upgraded by JPMorgan as operational turnaround nears
PositiveFinancial Markets
Bellevue Gold's stock has been upgraded by JPMorgan, signaling a positive outlook as the company approaches a significant operational turnaround. This upgrade reflects confidence in Bellevue Gold's ability to enhance its performance in the competitive gold market.
Oil edges down as investors assess oversupply, geopolitics
NeutralFinancial Markets
Oil prices have edged down as investors assess the ongoing oversupply in the market and geopolitical tensions affecting global trade. Recent reports indicate that crude oil inventories are surging, contributing to a bearish outlook for prices in the near future.
Brown Forman stock price target maintained at $30 by RBC Capital
NeutralFinancial Markets
RBC Capital has maintained its stock price target for Brown Forman at $30, indicating a stable outlook for the company amid fluctuating market conditions. This decision reflects RBC's confidence in Brown Forman's business model and market position.
McBrayer Brett buys Ampco Pittsburgh (AP) shares worth $48,944
NeutralFinancial Markets
McBrayer Brett has acquired shares of Ampco Pittsburgh valued at $48,944, as reported by Investing.com. This transaction highlights McBrayer's investment strategy and confidence in the company's future prospects.
Piper Sandler maintains Overweight rating on Chewy stock amid profitability debate
NeutralFinancial Markets
Piper Sandler has reaffirmed its Overweight rating on Chewy stock amidst ongoing discussions regarding the company's profitability. This decision reflects the investment firm's confidence in Chewy's potential for growth despite current market uncertainties.
Bank of England sees greater financial risks from AI and lending
NegativeFinancial Markets
The Bank of England has raised concerns about increasing financial risks stemming from artificial intelligence (AI) and lending practices, highlighting the potential for instability in the financial system. This warning comes amid a backdrop of significant debt-fueled investments in AI infrastructure, which the central bank believes could lead to adverse market conditions.
Harrington sells Cytokinetics (CYTK) stock worth $143,620
NeutralFinancial Markets
Harrington has sold shares of Cytokinetics (CYTK) stock valued at $143,620, a transaction reported by Investing.com. This sale reflects Harrington's financial decisions regarding his investment in the biopharmaceutical company, which focuses on developing treatments for debilitating diseases.